You are here

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Aspergillosis, Invasive Pulmonary Aspergillosis, Neuroaspergillosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-17 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of proven, probable, or possible invasive aspergillosis.

- Hematologic malignancy or allogeneic hematopoetic stem cell transplant.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.

- Chronic invasive aspergillosis.

- Receipt of antifungal treatment for more than 96 hours.

- Severe liver dysfunction.

NCT01188759
Pfizer
Withdrawn
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

Clini[email protected]

Call Now